Stay updated with breaking news from Aemolytic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PARIS (dpa-AFX) - Sanofi - Aventis Groupe said that the European Commission has granted marketing authorization for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients
Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell diseaseSOUTH SAN FRANCISCO, Calif., July
LAS VEGAS, Feb. 28, 2022 /PRNewswire/ -- The launch of key Warm Autoimmune Hemolytic Anemia (WAIHA) assets such as Fostamitinib (Rigel Pharmaceuticals) and APL2 (Apellis Pharmaceuticals), which
The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis - the cause of long-term complications of sickle cell diseaseSOUTH
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion